Histopathological Changes In Rheumatoid Arthritis Biology Essay


Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints. It is associated with increased mortality rates as compared to the healthy population. The actual cause of rheumatoid arthritis is unknown although several factors accelerating its progression are outlined. This review enlists various histopathological changes and encompasses a note on its applicability in target specific delivery with the aid of antibodies. There are various first-line, second-line and newer biological treatments available. This review gives brief details of the novel approaches for the delivery of the targeted as well as non targeted systems like oral, topical, nasal and parenteral and the recent advancements that have been achieved. Moreover it also gives an account of the changes that can be made for future with the use of biotechnology like the application of gene profiling and gene array techniques.

Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints, tissue around the joints, as well as in other organs in the body and also causes cartilage and bone destruction and so it is referred to as a systemic disease or rheumatoid disease results in gradual immobility. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly attacked by their own immune system. Patients with autoimmune diseases have antibodies in their blood that target their own body tissues, where they can be associated with inflammation [1]. While rheumatoid arthritis is a chronic illness, meaning it can last for years. However, rheumatoid arthritis is typically a progressive illness that has the potential to cause joint destruction and functional disability. First it is noticed in American population and then reported in European population in 17th century [2]. Mainly treatment of arthritis meant for symptomatic relief and rehabitalization of individual. In practical world pain relievers and steroids are used to treat arthritis in most of the cases. Now days biological agents are being more popular. Use of Controlled and targeted therapy increases effectiveness, reduces dosing intervals and minimize dosing requirements. Combination therapy is showing better approach than prescribing individual agents to rheumatic patients.

Lady using a tablet
Lady using a tablet


Essay Writers

Lady Using Tablet

Get your grade
or your money back

using our Essay Writing Service!

Essay Writing Service

2. Impact of arthritis

2.1.1 Mortality and co-morbidities

Rheumatoid arthritis is a common rheumatic disease, affecting approximately 1.3 million people in the United States only, according to current census data. [1]. RA is associated with excess mortality compared with the general population. This excess mortality rate has been estimated at approximately 25% [3]. Cardiovascular disease is the most important co-morbid cause of death in patients with RA, being reported in 42% of RA patients [4], it is also due to treatment with methotrexate (MTX) or sulphasalazine, hypertension, renal disease and infections [5].

2.1.2 The economic impact of RA

The major driver for direct costs is inpatient care. However, the available very effective but costly treatments such as tumor necrosis factor (TNF) blocking agents may lead to medication being the major cost driver. The indirect costs are mostly due to the number of days absent from work. As a result, the indirect costs in working age patients due to work disability may be substantially higher than the direct costs. Functional disability is strongly correlated with the direct and indirect costs in RA [5-7].

3. Histopathological changes in rheumatoid arthritis

The cause of rheumatoid arthritis is unknown. Even though infectious agents such as viruses, bacteria, and fungi have long been suspected, none has been proven as the cause. It is believed that the tendency to develop rheumatoid arthritis may be genetically inherited. It is also suspected that certain infections or factors in the environment (smoking tobacco) might trigger the activation of the immune system in susceptible individuals. This leads to inflammation in the joints and sometimes in various organs of the body, such as the lungs or eyes. An inflamed synovium is central to the pathophysiology of rheumatoid arthritis. It is histologically striking, showing pronounced angiogenesis; cellular hyperplasia; an influx of inflammatory leucocytes including T cells, B cells, macrophages, and plasma cells; and changes in the expression of cell-surface adhesion molecules, proteinases, proteinase inhibitors, and many cytokines. Almost all of the inflammatory mediators linked to arthritis have been shown to be regulated by the transcription factor nuclear factor-kB (NF-kB) [8]. Synovial Fibroblast Lining and Deeper Synovial Fibroblast lining highly differ from each other in RA. NF-kB(transcription factor) is get activated in RA and plays important role in progression of disease and inflammation [9-12].

Lady using a tablet
Lady using a tablet


Writing Services

Lady Using Tablet

Always on Time

Marked to Standard

Order Now

Table 1. Inducers, Effects of Inducers and Various Targets of NF-kB for Treatment of RA [13].


Inducer of NF- kB




IL1, TNF -α

Inflammation; Expression of metalloproteinase and adhesion molecule; Prostaglandin production; Angiogenesis; Secretion of other cytokines

IL-1, IL-2, IL-6, IL-8, IL-15, IL-17, IL-18, TNF α

T Cell

CD40L, FasL

Recruitment of inflammatory cell

IL-8, MCP-1, ICAM-1, VCAM -1, GM -CSF


B Cell

CD20, CD40L, CD+4T Cell

T Cell activation ; Leucocyte infiltration ; Angiogenesis

IL-1, IL-4, IL-6, IL-10, TNF- α

Nerve growth factor

BDNF, NT-3, NT- 4, NT-5

Expression of IL 2 receptor on T and B cell; Activation of T cell, B cell Basophiles, PI 3 kinase, RAS, PLC; Migration of leucocytes; Mast cell degradation; NOS induction

MMP -1, TNF-α, IL-1, IL-2, IL-6, IL-8 ,IL-12, adhesion molecule, collagenase -1

Growth factor



TGF (TGF b1)

Activation of inflammatory cell; Promote chemotaxis




COX -2,


FGF (FGF acidic and FGF basic)

Inhibit type ІІ collagen and proteoglycan synthesis; Induction of MMPs; Production of prostaglandin and NO; Chemoattractant for endothelial cells


 Act as a mitogen; Chemoattractant for smooth muscle cell and macrophages; Induce expression of IL 1β, IL 8 and MMPs


IL-1β, IL-8,


Viral protein

HTLU-1 tax

Production of MMPs; Remodeling and destruction of extracellular matrix

MMP-1, MMP-3, MMP-9, MMP-13

Bacterial products


Oxidative stress

Superoxide, peroxide


C Myc, cyclin D

Ischemia/ Reperfusion


Radiation, chemotherapy

Anti apoptosis; Activation of anti apoptotic genes


c IAP-1, c IAP-2

4. Medication used for the Treatment of arthritis

There is no known cure for rheumatoid arthritis to date, the goal of treatment in rheumatoid arthritis is to reduce joint inflammation and pain, maximize joint function, and prevent joint destruction and deformity. First line agents are non steroidal anti-inflammatory drugs, selective COX-2 inhibitors and steroids. Second line agents includes disease modifying anti-rheumatic drugs and various biological agents [14-15]. First line agents are intended to suppress the pain manifested in arthritis; however these agents not supposed to prevent further destruction of joints. Second line agents mainly involve in prevention of joint destruction.

First-line medication

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Acetylsalicylate (aspirin), Naproxen (Naprosyn), Ibuprofen (Advil, Medipren), Etodolac (Lodine), Meloxicam, Nabumetone, Sulindac, Tolementin, Choline magnesium salicylate, Diclofenac, Diflusinal, Indomethicin, Ketoprofen, Oxaprozin, and Piroxicam are examples of NSAIDs. NSAIDs are first line medications that can reduce tissue inflammation, pain, and swelling. Aspirin, in doses higher than those used in treating headaches and fever, is an effective anti-inflammatory medication for rheumatoid arthritis. The most common side effects of aspirin and other NSAIDs include stomach upset, abdominal pain, ulcers, and even gastrointestinal bleeding [16].

COX-2 inhibitor

Celecoxib (Celebrex), Rofecoxib (Vioxx), Valdecoxib (Bextra). COX-2 inhibiters inhibit the action of COX-2 enzyme found in inflamed area. COX-2 inhibitor prevent production of three main groups of prostanoids - prostaglandins, prostacyclins, and thromboxanes thus reduces inflammation and relieves pain more selectively and efficiently than NSAIDs [17]


Betamethasone (Celestone), Budesonide (Entocort), Cortisone (Cortone), Dexamethasone (Decadron), Hydrocortisone (Cortef), Methylprednisolone (Medrol), Prednisolone (Prelone), Prednisone (Deltasone), Triamcinolone (Kenacort). Corticosteroid medications can be given orally or injected directly into tissues and joints. They are more potent than NSAIDs in reducing inflammation and in restoring joint mobility and function. Corticosteroids are useful for short periods during severe flares of disease activity or when the disease is not responding to NSAIDs. Corticosteroids acts by inhibiting induction of COX enzyme, inhibiting release of collagenase and lysosomal enzymes, and reducing macrophage phagocytosis and IL-1 secretion [18]. Glucocorticoids act like immuno-suppressants and consequently cytokine genes transcription is demolished[16]. However, they also impede the function of white blood cells which destroy foreign bodies and help keep the immune system functioning properly. The interference with white blood cell function yields a side effect of increased susceptibility to infection. Other side effects associated with corticosteroids, especially when given in high doses for long periods of time include weight gain, facial puffiness, thinning of the skin and bone, easy bruising, cataracts, muscle wasting, and destruction of large joints, such as the hips [1, 37].

Lady using a tablet
Lady using a tablet

This Essay is

a Student's Work

Lady Using Tablet

This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.

Examples of our work

4.1.2 Second line medication

Disease-modifying antirheumatic drugs

While first line medications (NSAIDs and corticosteroids) can relieve joint inflammation and pain, they do not necessarily prevent joint destruction or deformity. Rheumatoid arthritis requires medications other than NSAIDs and corticosteroids to stop progressive damage to cartilage, bone, and adjacent soft tissues. These second lines or slow acting or disease modifying antirheumatic drugs may take weeks to months to become effective. They are used for long periods of time, even years, at varying doses. Sometimes a number of DMARD second-line medications are used together as combination therapy. DMARDs are immunosuppressant and they are associated with some common side effects like, skin rash, sore mouth, kidney damage with leakage of protein in the urine, and bone marrow damage with anemia and low white cell count, fever, chills, a metallic taste in the mouth, stomach upset, and easy bruising [16].

Table 2.DMARDs and Biological response modifiers with their mechanism of actions




Chloroquine and Hydroxychloroquine (Ploquenil) (antimalarials)

Sulphasalazine (Azulfidine)

Suppression of IL-1 & TNF-α induce apoptosis of inflammatory cells and increase chemotactic factors

Gold salts 

Aurothiomalate (Myochrysine), Thioglucose (Solganal), Auranofin (Ridaura)

Inhibits macrophage activation

Azathioprine (Imuran)

Purine synthesis inhibitor

Cyclosporin A (Sundimmun)

Inhibit calcineurin

D-penicillamine (Depen)

Reducing numbers of T-lymphocytes

Leflunomide (Arava)

Pyrimidine synthesis inhibitor

Methotrexate (Rheumatrex)


Minocycline (Dynacin, Minocin)

5-LO inhibitor




Etanercept (Enbrel), Golimumab (Simponi), Adalimumab (Humira), Infliximab(Remicade)

TNF inhibitor

Anakinra (Kineret), Canakinumab (Llaris)

IL-1 inhibitor

Basiliximab (Simulect), Daclizumab (Zenapex)

IL-2 inhibitor

Atlizumab (Actemra)

IL-6 inhibitor

Rituximab (Rituximab)

Chimeric monoclonal antibody against CD20 on B cell surface


Antibody against CD3 on T cell

Zonolimumab (Hu-Max)

Antibody against CD4 on T cell

Denosumab (Prolia)

Antibody against RANKL

Biological agents

Biological agents are biological response modifiers (BRMs). BRMs are specific antibodies against the inflammatory agents responsible for production of pain in RA. They alter the response produced by inflammatory agents and thus reduce pain more effectively and more specifically. BRMs are effective in reduction of pain associated with RA but they have some serious side effects like redness, irritation and increased risk of infection; may be associated with multiple sclerosis-like reactions and possibly, increased risk of lymphoma [19].

4.1.3 Natural approaches

Because current treatments for arthritis result in unwanted side effects and tend to be expensive, natural products devoid of such disadvantages and offer a novel opportunity. Agents derived from plants that can modulate the expression of pro-inflammatory signals clearly have potential against arthritis. These include flavonoids, terpenes, quinones, catechins, alkaloids, polyphenols, anthocyanins and anthoxanthins, all of which are known to have anti-inflammatory effects.

Table 3.Molecular targets of natural compounds that have anti arthritic activity [20-30]



Molecular targets

Boswellic acid

Boswellia serrata (Salai guggul)

NF-kB, COX-2, 5-LOX, MMP-9, ICAM-1


Berberis vulgaris (barberry)

NF-kB, COX-2, TNF-a, IL-1b, IL-6


Cayaponia tayuya

NF-kB, COX-2, TNF-a


Curcuma longa

NF-kB, COX-2, 5-LOX, TNF-a, IL-1b, IL-6, IL-8, MMPs,


Syzygium aromaticum (cloves)

NF-kB, COX-2, 5-LOX, TNF-a, IL-1b


Commiphora mukul (guggul)

NF-kB, COX-2, MMP-9


Allium cepa (onions)

NF-kB, COX-2, TNF-a, 5-LOX, TNF-a, IL-1b, Ams


Vitis vinifera (red grapes)

NF-kB, COX-2, TNF-a, 5-LOX, AMs


Aspergillus terreus (yeast)

NF-kB, COX-2, MMP-9, AMs

Ursolic acid

Ocimum sanctum (holy basil)

NF-kB, COX-2, MMP-9


Withania somnifera

NF-kB, COX-2, MMP-9, ICAM-1

5. Various Approaches for the Treatment of RA

Systemic side effects of orally administered NSAIDs, corticosteroids and DMARDs used to treat RA involves bone loss, osteoporosis, peptic ulcers and buffalo hump, special drug delivery systems are required to deliver them to the site of action(targeted) and designed to provide targeted and controlled drug delivery with minimum side effects. We can incorporate the API in novel drug delivery systems like, SLN (Solid Lipid Nano particles), Nano Lipid Vesicles, Liposomes, Hydro gels, Specially Coated Tablets and Capsules, Pulse Release Tablets, Patches, Depot formation, Controlled release microchip, Polymeric carriers, Resealed erythrosomes, which provides optimum, controlled, effective and targeted drug release profile [31].

5.1. Oral route

Most common and conventional and preferred route of drug administration is oral route. Most of the drugs used in treatment of RA are administered by oral route. Because of the frequent administration and side effects of orally administered medication following approaches are made for desired release profile like extended release dosage forms.

Extended Release dosage forms fall into one of the following two technologies:

A. Hydrophilic, hydrophobic or inert matrix systems: These consist of a rate controlling Polymer matrix through which the drug is dissolved or dispersed.

B. Reservoir (coated) systems: Where drug-containing core is enclosed within polymer coatings. Depending on the polymer used, two types of reservoir systems are considered

(a) Simple diffusion/erosion systems: Where a drug-containing core is enclosed within hydrophilic and/or water-insoluble polymer coatings. Drug release is achieved by diffusion of the drug through the coating or after the erosion of the polymer coating.

(b) Osmotic systems: Where the drug core is contained within a semi-permeable polymer membrane with a mechanical/laser drilled hole for drug delivery. Drug release is achieved by osmotic pressure generated within the tablet core [32].

Micro-porous membrane coating on the soluble salts of indomethacine is done by pelletization technique and it will result in extended release formulation [33]. Other approach is Pulsatile drug delivery system which involves release of drug from the formulation on specific intervals with lag phases [34]. Combination product of NSAID's and steroids can provide better care with minimum gastric erosion and that is proved by marketed formulation Arthrotec® (Diclofenac Sodium and Misoprotol) [35, 36].

Controlled-Release Microchip: The conventional controlled drug release from polymeric materials is in response to specific stimuli such as electric and magnetic fields, ultrasound, light, enzymes. Microchip technology has been applied to achieve pulsatile release of liquid solutions. A solid-state silicon microchip was invented at the Massachusetts Institute of Technology (Cambridge, MA), which incorporates micrometer-scale pumps and flow channels to provide controlled release of single or multiple chemical substances on demand [37].

5.2. Parenteral route

Parentral route of drug administration is the second highly preferred route for the treatment of RA as administration of certain drugs and biological can be done by only this route and also provide immediate relief. But non-convenience and not possible self-administration are main drawbacks.

PLA and PLGA Nanoparticles encapsulating anti-arthritic drugs gives both targeted as well as sustained drug delivery. Higaki et al studied that glycolic acid nanoparticles containing corticosteroids will provide slow release and targeted delivery [39].

Humira® pen and SimpleJect™ are examples of self administration devices available in the market. Both of these are delivered through sub-cutaneous route and provide drastic relief in rheumatic pain [40, 41].

Lipid Microspheres, liposome and co-polymeric blocks are excellent carriers among the all other carriers for Parentral administration because they provide high stability and safety [42]. Microspheres are best carrier for stable as well as fragile drug molecules, they increases patient comfort and compliance. Lipid microspheres have additional benefits like they provide targeted approach as they tend to accumulated in the inflamed area and by nature they provide controlled release [43]. Liposome is showing same advantages as lipid microspheres, Prednisolone containing TRX-20 liposome is the best example [44]. Microsphere and liposome can also be used in combination therapy. A combination of methotrexate and monoclonal antibody within liposome is well known example. Drug is encapsulated within liposome and antibody is attached to liposome provides two important functions: controlled and targeted release.

5.3. Topical route

Gastric bleeding and peptic ulcer are the major side effects in systemic drug delivery of NSAIDs and which is easily overcome by topical route [45]. Poloxomer containing Methotrexate is one of the example showing feasibility of topical route of administration, it produces higher drug concentration at the site of the action beneath the skin [46]. Iontophoresis is special method for delivering the drug across the barriers of the skin by applying electric transmission, applied potential pushes the drug molecule to penetrate across the skin. Cannabidiol used to treat RA but shows number of systemic side effects when administered orally, however iontophoretic trans-dermal administration prevent inflammation and edema [47]. Oleo Hydrogel is lipid micro or nano emulsion which enhances absorption and penetration, also addition of penetration enhancers like DMSO increases effectiveness of topical formulation.

In RA hypoxia is common so this can be utilize as to target our drug to hypoxic joint. Bioreductive drug targeting involves the same mechanism that oxygen suppresses the release of the drug while lack of it cause release. Self alkylating system involves conversion of nucleophile into bioreductive structure to favor intramolecular cyclisation over nucleophilic attack from DNA molecules [48].

Intranasal route

Nasal route provides effective, convenient, accurate and repeatable dosing. Intranasal route of drug administration provides total bioavailability as same as Parentral or more than that. It is non-invasive and rapid acting route of drug administration [49]. Glycoprotein-39 administration in mice model through intranasal route shows effective treatment of RA [50].

Future treatments

Studies involving various types of the connective tissue collagen are in progress and show encouraging signs of reducing rheumatoid disease activity. Finally, genetic research and engineering is likely to bring forth many new avenues for earlier diagnosis and accurate treatment in the near future. Gene profiling, also known as gene array analysis, is being identified as a helpful method of defining which people will respond to which medications. Studies are under way that is using gene array analysis to determine which patients will be at more risk for more aggressive disease. This is all occurring because of improvements in technology.


Pharmacological therapy is the cornerstone in the management of established RA. Pharmacological and non-pharmacological therapies are necessary to reach these goals. This management plan may be adjusted during patient follow-up using information from measurements of disease activity, disability and joint damage. The ability of the new biological response modifiers to intervene in the disease process has generated enthusiasm for therapeutic interventions and for the possibility of future drugs that target individual inflammatory pathways. However, this excitement is tempered by the potential for long-term side-effects and toxicity.

Generally, MTX is regarded as the first choice in the DMARD, and MTX is most often used in combination strategies. Combinations of MTX and TNF blocking agents and MTX with sulphasalazine and/or hydroxychloroquine have shown good efficacy/toxicity ratios. Intramuscular gold, have also been shown to be effective in clinical trials. For optimal treatment in clinical practice, a longitudinal management plan should be defined for each individual patient with established RA, including the goals of treatment. However, it is difficult to predict how patients will respond to first line and second line therapy. Patients not responding to initial therapy are candidates for therapy change including combination strategies.